Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced?

Recursion Pharmaceuticals (RXRX) is back in focus after its latest earnings materials highlighted encouraging safety data for REC-1245 and strong Phase 2 results for REC-4881, alongside ongoing FDA discussions and fresh buying interest from ARK Investment.

See our latest analysis for Recursion Pharmaceuticals.

Despite the latest clinical updates and ARK Investment interest, Recursion Pharmaceuticals’ recent momentum has cooled, with the share price down 6.3% over the past week after a 17.1% 1 month share price return. The 1 year total shareholder return is down 32.6%.

If this kind of high risk biotech story grabs your attention, it can be useful to see what else is moving in healthcare AI, starting with 41 healthcare AI stocks

After a sharp 1 month rebound but a weaker 1 year return, the question around Recursion Pharmaceuticals now is whether recent optimism already reflects the key catalysts or if the current valuation still leaves meaningful upside on the table.

Most Popular Narrative: 80.7% Overvalued

According to the most followed narrative on Recursion Pharmaceuticals, the fair value is set at $1.97, well below the last close at $3.56. This sets up a very different picture from recent share price action.

RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said

Read the complete narrative.

The narrative behind that $1.97 fair value leans heavily on aggressive revenue assumptions, margin shifts and a rich future earnings multiple that only a few high growth biotech platforms usually command. It raises questions about which specific forecast levers are doing most of the heavy lifting in that calculation and how they compare with Recursion Pharmaceuticals’ current loss profile and pipeline stage mix.

Result: Fair Value of $1.97 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Recursion Pharmaceuticals could see this overvalued view challenged if FDA discussions advance favorably or if REC-4881 and REC-1245 deliver clearer late stage visibility.

Find out about the key risks to this Recursion Pharmaceuticals narrative.

Another View: SWS DCF fair value for Recursion Pharmaceuticals

While the most followed narrative sees Recursion Pharmaceuticals as overvalued at a $1.97 fair value, the SWS DCF model points the other way with an estimate of $10.13 per share versus the current $3.56 price, implying the stock trades at a 64.9% discount.

That gap reflects two very different stories about long term cash generation. The real question for you is which assumptions feel closer to how Recursion’s pipeline and spending could evolve over time.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such mixed sentiment around Recursion Pharmaceuticals, it makes sense to move quickly from headlines to hard numbers and decide where you stand. To see how the upside potential stacks up against the concerns being raised, review the balance of risks and rewards in the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Recursion Pharmaceuticals?

Do not stop with Recursion Pharmaceuticals when there are other opportunities worth checking. Use focused stock lists to quickly spot ideas that better match your approach.

• Target potential value opportunities by scanning companies that look mispriced on quality and fundamentals using the 44 high quality undervalued stocks.
• Strengthen your portfolio foundation by reviewing stocks with robust finances and sensible metrics through the solid balance sheet and fundamentals stocks screener (47 results).
• Get ahead of the crowd by checking a screener containing 19 high quality undiscovered gems before attention and liquidity potentially move elsewhere.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com